15 completed, 3 terminated, 3 withdrawn, 1 active not recruiting. 13 Phase 2, 7 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 9, Terminated 2, Withdrawn 2 |
| Phase 1 | 7 | Completed 5, Terminated 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow Vipoma: new trials by email Literature Review of Vipoma trials Research Report on Vipoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs 177Lu-DOTATOC - Neuroendocrine Tumors, Carcinoid Tumor | Phase 2 | Withdrawn | British Columbia Cancer Agency | 2023-01-15 | 2023-02-21 | |
| DOTATOC PET/CT for Imaging NET Patients 68Ga-DOTATOC PET/CT, 18F-FDG PET/CT - Neuroendocrine Tumors, Insulinoma | Active not recruiting | British Columbia Cancer Agency | 800 | 2018-07-11 | 2026-05-12 | |
| Laser Tissue Welding - Distal Pancreatectomy Sealing Study Distal Pancreatectomy Sealing Using LTW - Pancreatic Tumor, Benign, Pancreatic Neoplasms | Phase 1 | Completed | Laser Tissue Welding, Inc. | 11 | 2018-01-01 | 2022-04-06 |
| Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Capecitabine, Temozolomide, Veliparib - Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma | Phase 1 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2017-12-01 | 2017-09-28 | |
| Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Bevacizumab, Everolimus, Octreotide Acetate - Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor | Phase 2 | Completed | National Cancer Institute (NCI) | 150 | 2010-10-15 | 2022-08-04 |
| AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors AMG 706, octreotide - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Eastern Cooperative Oncology Group | 46 | 2008-11-07 | 2023-07-05 |
| Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Fentanyl sublingual spray, Placebo - Cancer | Phase 3 | Completed | INSYS Therapeutics Inc | 130 | 2007-10-01 | 2014-03-05 |
| Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors questionnaire administration, quality-of-life assessment - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Unknown | National Cancer Institute (NCI) | 408 | 2006-10-01 | 2013-10-29 | |
| Capecitabine and Temozolomide for Neuroendocrine Cancers Capecitabine, Temozolomide - Neuroendocrine Tumors | Phase 2 | Completed | Columbia University | 41 | 2005-08-01 | 2016-07-25 |
| Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors bevacizumab, 5-fluorouracil, leucovorin - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 / Phase 3 | Terminated | University of California, San Francisco | 36 | 2005-06-08 | 2023-05-22 |
| Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors sorafenib tosylate - Gastrinoma, Glucagonoma | Phase 2 | Completed | National Cancer Institute (NCI) | 93 | 2005-06-01 | 2014-11-17 |
| Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer isolated perfusion, melphalan - Cancer | Phase 2 | Completed | Delcath Systems Inc. | 56 | 2004-09-01 | 2013-10-23 |
| Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery fluorouracil, irinotecan hydrochloride, leucovorin calcium - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Federation Francophone de Cancerologie Digestive | 20 | 2004-05-01 | 2016-05-30 |
| Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors gefitinib, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Completed | National Cancer Institute (NCI) | 90 | 2003-12-01 | 2013-06-04 |
| Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors octreotide acetate, yttrium Y 90 resin microspheres - Head and Neck Cancer, Islet Cell Tumor | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 10 | 2003-12-01 | 2012-05-18 |
| EPO906 in Carcinoid and Other Neuroendocrine Tumors EPO906 epothilone B - Carcinoid, Neuroendocrine Tumors | Phase 2 | Completed | Novartis Pharmaceuticals | 33 | 2002-07-01 | 2017-03-01 |
| Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors thalidomide - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 2001-03-01 | 2013-06-18 | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer trastuzumab, tipifarnib - Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2000-06-01 | 2013-02-11 |
| Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum floxuridine, leucovorin calcium, oxaliplatin - Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 2000-04-01 | 2011-04-26 | |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu recombinant interleukin-12, ABI-007/carboplatin/trastuzumab - Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 15 | 1999-08-01 | 2013-02-28 |
Showing 20 of 23. Sign in to see all of them.
Insulinoma (20) · Gastrinoma (19) · Glucagonoma (19) · Somatostatinoma (18) · Carcinoma, Islet Cell (15) · Neoplasms (13) · Adenoma, Islet Cell (9) · Carcinoma, Medullary (8) · Neuroendocrine Tumors (8) · Pancreatic Neoplasms (7) · Pheochromocytoma (7) · Appendiceal Neoplasms (5) · Bile Duct Neoplasms (5) · Carcinoid Tumor (5)
Adenocarcinoma (23) · Carcinoma, Neuroendocrine (23) · Digestive System Diseases (23) · Digestive System Neoplasms (23) · Endocrine Gland Neoplasms (23) · Endocrine System Diseases (23) · Neoplasms by Histologic Type (23) · Neoplasms by Site (23) · Neoplasms, Germ Cell and Embryonal (23) · Neoplasms, Glandular and Epithelial (23) · Neuroectodermal Tumors (23) · Pancreatic Diseases (23) · Carcinoma (22) · Adenoma (20) · Neoplasms, Nerve Tissue (16)
Octreotide (4) · Leucovorin (3) · Bevacizumab (2) · Capecitabine (2) · Fluorouracil (2) · Oxaliplatin (2) · Temozolomide (2) · Trastuzumab (2) · 177Lu-octreotide, DOTA(0)-Tyr(3)- (1) · 90Y-octreotide, DOTA-Tyr(3)- (1) · Acetates (1) · Biological Therapy (1) · Disulfides (1) · Everolimus (1) · Fentanyl (1)
National Cancer Institute (NCI) (6) · British Columbia Cancer Agency (2) · Eastern Cooperative Oncology Group (2) · Memorial Sloan Kettering Cancer Center (2) · Novartis Pharmaceuticals (2) · Vanderbilt-Ingram Cancer Center (2) · Columbia University (1) · Delcath Systems Inc. (1) · Federation Francophone de Cancerologie Digestive (1) · INSYS Therapeutics Inc (1) · Laser Tissue Welding, Inc. (1) · University of California, San Francisco (1) · Yale University (1)
United States (17) · Canada (3) · Denmark (1) · Germany (1) · Greece (1) · Israel (1) · Italy (1) · Netherlands (1) · Poland (1) · Spain (1) · Sweden (1) · United Kingdom (1)
Francois Benard, MD (2) · Leonard B. Saltz, MD (2) · Mary Mulcahy, MD (2) · Timothy Hobday (2) · Anthony W. Tolcher, MD (1) · Emily K. Bergsland, MD (1) · Guillaume Cadiot (1) · John K. Ramage, MD (1) · John R. Murren, MD (1) · Jordan Berlin, M.D. (1) · Kyle Holen, MD (1) · Larry Dillaha, MD (1) · Larry K. Kvols, MD (1) · Marybeth Hughes, MD (1) · Matthew H Kulke (1)
PMID 21831734, PMID 22480131, PMID 27020837, PMID 29853660
N01CM62205 (2), R44CA203052 (1), U01CA076576 (1), U10CA023318 (1), U10CA031946 (1), U10CA180821 (1)